Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility: HELP
Articles by Philippe Morice
Based on 12 articles published since 2008

Between 2008 and 2019, P. Morice wrote the following 12 articles about Infertility.
+ Citations + Abstracts
1 Guideline [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]. 2018

Rousset-Jablonski, Christine / Selle, Fréderic / Adda-Herzog, Elodie / Planchamp, François / Selleret, Lise / Pomel, Christophe / Chabbert-Buffet, Nathalie / Daraï, Emile / Pautier, Patricia / Trémollières, Florence / Guyon, Frederic / Rouzier, Roman / Laurence, Valérie / Chopin, Nicolas / Faure-Conter, Cécile / Bentivegna, Enrica / Vacher-Lavenu, Marie-Cécile / Lhomme, Catherine / Floquet, Anne / Treilleux, Isabelle / Lecuru, Fabrice / Gouy, Sébastien / Kalbacher, Elsa / Genestie, Catherine / de la Motte Rouge, Thibault / Ferron, Gwenael / Devouassoux-Shisheboran, Mojgan / Kurtz, Jean-Emmanuel / Namer, Moise / Joly, Florence / Pujade-Lauraine, Eric / Grynberg, Michael / Querleu, Denis / Morice, Philippe / Gompel, Anne / Ray-Coquard, Isabelle. ·Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. · Groupe hospitalier Diaconesses Croix-Saint-Simon, 12-18, rue du Sergent-Bauchat, 75012 Paris, France. · Hôpital Foch, service de gynécologie-obstétrique, 40, rue Worth, 92151 Suresnes, France. · Institut Bergonié, 229, Cours-de-l'Argonne, 33000 Bordeaux, France. · Hôpital Tenon, service de gynécologie-obstétrique et médecine de la reproduction, 4, rue de la Chine, 75020 Paris, France. · Centre Jean-Perrin, 58, rue Montalembert BP, 392, 63011 Clermont-Ferrand cedex 1, France. · Institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94800 Villejuif, France. · Hôpital Paule-de-Viguier, centre de ménopause et de dépistage de l'ostéoporose, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France. · Hôpital Cochin-Port Royal, 53, avenue de l'Observatoire, 75014 Paris, France. · Hôpital Européen Geroges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · CHU Besançon-Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France. · Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France. · CLCC, institut Claudius-Regaud, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. · Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. · CHU de Strasbourg, hôpital de Hautepierre, avenue Molière, 67200 Strasbourg, France. · Recommandations pour la pratique clinique, Nice-Saint-Paul, 06000 Nice, France. · Centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France. · CHU Paris Centre, hôpital Hôtel-Dieu, 1, place du Parvis-Notre-Dame, 75004 Paris, France. · Hôpital Jean-Verdier, avenue du 14 juillet, 93140 Bondy, France. ·Bull Cancer · Pubmed #29397916.

ABSTRACT: INTRODUCTION: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. METHODS: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. RESULTS: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. DISCUSSION: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

2 Guideline Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. 2011

Morice, Philippe / Denschlag, Dominik / Rodolakis, Alex / Reed, Nick / Schneider, Achim / Kesic, Vesna / Colombo, Nicoletta / Anonymous2750698. ·ESGO Task Force for Fertility Preservation in Gynecological Cancer, Geneva, Switzerland. morice@igr.fr ·Int J Gynecol Cancer · Pubmed #21697684.

ABSTRACT: In young patients with borderline ovarian tumor a conservative treatment approach does not seem to have a significant impact on survival, and the outcome regarding fertility is good in general. It can be considered even if noninvasive peritoneal implants are discovered at the time of the initial surgery. In contrast, in patients with epithelial ovarian cancer, conservative surgery should be considered only in adequately staged patients, with a stage IA grade 1 (and probably 2) serous, mucinous or an endometrioid tumor, including a careful follow-up. Such an approach could also probably be discussed in stage IC grade 1 disease.In patients with nonepithelial malignant ovarian tumors, conservative surgery is also feasible, particularly in patients with malignant germ cell tumors because of their high chemosensitivity leading to an excellent prognosis in general.

3 Review Gynaecologic cancer surgery and preservation of fertility. 2018

Bentivegna, E / Maulard, A / Miailhe, G / Gouy, S / Morice, P. ·Département de chirurgie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94085 Villejuif cedex, France. Electronic address: enrica.bentivegna@gustaveroussy.fr. · Département de chirurgie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94085 Villejuif cedex, France. ·J Visc Surg · Pubmed #29735328.

ABSTRACT: For gynecological cancers, even at an early stage, the standard treatment is "radical excision" involving hysterectomy (radical or not) with bilateral salpingo-oophorectomy. But for young patients with early stage disease, many recent studies have focused on preservation of subsequent fertility by keeping at least one ovary and the uterus. The main objective of this fertility-sparing surgery is to preserve fertility, if this can be accomplished without increasing the oncological risks. Whether the initial site of the cancer is the cervix, uterine fundus or ovary, the oncologic validation of fertility-sparing treatment requires several evaluation criteria: a rigorous clinical, radiological and surgical staging to verify that the pathology is truly at an early initial stage; expert pathologic interpretation of biopsy specimens to validate the histological criteria of "good prognosis"; provision of complete and understandable patient education verifying the true objectives for this fertility-sparing treatment (whose intent is to retain a potential for subsequent fertility without guaranteeing it) and provision of an explanation of the oncological constraints and implications of fertility-sparing surgery in the event of a possible pregnancy. As always in oncology, this strategy demands teamwork requiring successive discussions with the patient and spouse and thorough discussion of the oncological safety of this fertility-sparing strategy in multidisciplinary consultation meetings before "giving a green light".

4 Review Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. 2016

Bentivegna, Enrica / Maulard, Amandine / Pautier, Patricia / Chargari, Cyrus / Gouy, Sebastien / Morice, Philippe. ·Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France. · Department of Medical Oncology, Gustave Roussy, Villejuif, France. · Department of Radiation Oncology, Gustave Roussy, Villejuif, France. · Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France; Unit Institut national de la santé et de la recherche médicale, Villejuif, France; University Paris Sud, Le Kremlin Bicetre, France. Electronic address: morice@igr.fr. ·Fertil Steril · Pubmed #27430207.

ABSTRACT: OBJECTIVES: To evaluate the fertility results, obstetric outcomes, and the management of infertility in patients submitted to fertility-sparing surgery (FSS) for invasive cervical cancer. DESIGN: Systematic review. SETTING: Not applicable. PATIENT(S): Patients submitted to FSS for invasive cervical cancer (stage IB). INTERVENTION(S): Five different FSS procedures were studied. MAIN OUTCOMES MEASURE(S): Fertility, pregnancy outcomes, and management of infertility. RESULT(S): A total of 2,777 patients submitted to FSS and 944 ensuing pregnancies were included in this review. Five different surgical procedures were performed and studied. The overall fertility, live birth, and prematurity rates after these procedures were, respectively, 55%, 70%, and 38%. The pregnancy rate was higher in patients submitted to a vaginal or minimally invasive radical trachelectomy compared with a laparotomic radical trachelectomy. The live birth rate was similar, whatever the FSS procedure. The prematurity rate was significantly lower in patients who had undergone a simple trachelectomy/cone resection and neoadjuvant chemotherapy followed by FSS compared with other conservative surgeries. A majority of second trimester fetal losses and premature deliveries were related to premature rupture of membranes. CONCLUSION(S): The choice between the different FSS procedures depends first and foremost on the oncologic characteristics of the tumor. Nevertheless, when several options seem to offer the same oncologic results (for example, stage IB1 disease >2 cm), fertility results should then be taken into consideration to select the best choice acceptable to the patient/couple.

5 Review Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. 2016

Bentivegna, Enrica / Gouy, Sebastien / Maulard, Amandine / Chargari, Cyrus / Leary, Alexandra / Morice, Philippe. ·Department of Gynaecological Surgery, Institut Gustave Roussy, Villejuif, France. · Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. · Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Unit INSERM U 981, Gustave Roussy, Villejuif, France. · Department of Gynaecological Surgery, Institut Gustave Roussy, Villejuif, France; Unit INSERM U 10-30, Gustave Roussy, Villejuif, France; University Paris-Sud (Paris XI), Le Kremlin Bicêtre, France. Electronic address: philippe.morice@gustaveroussy.fr. ·Lancet Oncol · Pubmed #27299280.

ABSTRACT: Fertility preservation in young patients with cervical cancer is suitable only for patients with good prognostic factors and disease amenable to surgery without adjuvant therapy. Consequently, it is only offered to patients with early-stage disease (stage IB tumours <4 cm), negative nodes, and non-aggressive histological subtypes. To determine whether fertility preservation is suitable, the first step is pelvic-node dissection to establish nodal spread. Tumour size (≤2 cm vs >2 cm) and lymphovascular space invasion status are two main factors to determine the best fertility-sparing surgical technique. In this systematic Review, we assess six different techniques that are available to preserve fertility (Dargent's procedure, simple trachelectomy or cone resection, neoadjuvant chemotherapy with conservative surgery, and laparotomic, laparoscopic and robot-assisted abdominal radical trachelectomy). The choice between the six different fertility preservation techniques should be based on the experience of the team, discussion with the patient or couple, and, above all, objective oncological data to balance the best chance for cure with optimum fertility results for each procedure.

6 Clinical Trial Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary. 2010

Kane, Aminata / Uzan, Catherine / Gouy, Sebastien / Pautier, Patricia / Duvillard, Pierre / Morice, Philippe. ·Institut Gustave Roussy, Villejuif, France. ·Fertil Steril · Pubmed #20537629.

ABSTRACT: The outcomes of 18 patients treated with pure laparoscopic management (treated conservatively in 14 patients) of serous borderline ovarian tumors with peritoneal implants were reviewed. Eight patients relapsed (three with an invasive recurrence), but none of the patients without residual disease at the end of surgery, or invasive implants or disease with a micropapillary pattern relapsed under the form of invasive carcinoma.

7 Article [Comparison of epidemiological factors between serous and mucinous borderline ovarian tumors: therapeutic implications]. 2012

Fauvet, Raffaèle / Demblocque, Élodie / Morice, Philippe / Querleu, Denis / Gondry, Jean / Daraï, Émile. ·CHU d'Amiens, centre de gynécologie obstétrique, 124, rue Camille-Desmoulins, 80054 Amiens, France. fauvet.raffaele@chu-amiens.fr ·Bull Cancer · Pubmed #22510207.

ABSTRACT: The goals of this multicenter French retrospective study were to compare epidemiological factors within borderline ovarian tumors (BOT) according to their serous (SBOT) or mucinous (MBOT) type and according to the presence of pejorative histological criteria. We analysed 224 SBOT and 164 MBOT diagnosed between 1990 and 2009. The patients mean age was not different according to serous or mucinous type (46.9 ± 16.7 years and 44.6 ± 17.6 years). Women with SBOT, had more frequently history of infertility (17.2% versus 3.9%, P < 0.0001) than women with MBOT. SBOT were more often asymptomatic (52.3% versus 33.5%, P < 0.001), bilateral (26.4% versus 4.3%, P = 0.0001), smaller (9.1 cm versus 14.5 cm, P = 0.0001) and diagnosed at advanced stage (81.2% of stage I versus 95.1%, P < 0.0001) than MBOT. The micropapillary pattern found in 10.3% of SBOT was observed at younger age (38 ± 15.4 years versus 47.9 ± 16.6 years, P = 0.007) and was more often associated with peritoneal implants (26.1% versus 6.5%, P = 0.02). The intraepithelial carcinoma found in 6.7% of MBOT, was more often associated with micro-invasion (36.4% versus 4.6%, P = 0.003). The existence of epidemiologic differences between SBOT and MBOT underlines that the BOT series analysis can not be considered without taking into account this parameter.

8 Article Fertility determinants after conservative surgery for mucinous borderline tumours of the ovary (excluding peritoneal pseudomyxoma). 2011

Koskas, Martin / Uzan, Catherine / Gouy, Sebastien / Pautier, Patricia / Lhommé, Catherine / Haie-Meder, Christine / Duvillard, Pierre / Morice, Philippe. ·Department of Gynecologic Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. ·Hum Reprod · Pubmed #21262776.

ABSTRACT: BACKGROUND The aim of this study was to define determinants of fertility in patients treated conservatively for mucinous borderline ovarian tumours (MBOTs), and to compare outcomes after salpingo-oophorectomy or cystectomy. METHODS This was a retrospective cohort study of fertility results in a series of patients treated conservatively for MBOTs and desiring pregnancy. Conservative surgery was defined as preservation of the uterus and ovarian tissue in one or both adnexa(e). Fertility results were compared with patients who had undergone a cystectomy or a (salpingo-)oophorectomy. Only patients with a minimum of 1 year of follow-up were included. Epidemiological, surgical, histological parameters and other prognostic factors for fertility results were investigated. RESULTS A group of 31 patients who had been treated conservatively between 1997 and 2004 and who desired pregnancy were investigated. Patients were treated by unilateral salpingo-oophorectomy (USO) (n = 19) or cystectomy (n = 12). The 5-year recurrence-free survival rate was higher in the USO group compared with the cystectomy group (94.7 versus 49.1%, P = 0.041). Among the 31 women, 12 had become pregnant. The 5-year probabilities of pregnancy were comparable between the cystectomy and salpingo-oophorectomy groups (41.8 and 45.9%, respectively, P= 0.66). None of the other factors studied (epidemiological, surgical and histological parameters) were associated with fertility results. CONCLUSIONS The use of salpingo-oophorectomy rather than cystectomy should be preferred during conservative surgery for patients with MBOTs because it decreases the risk of recurrence and does not impair fertility.

9 Article Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. 2011

de La Motte Rouge, Thibault / Pautier, Patricia / Rey, Annie / Duvillard, Pierre / Kerbrat, Pierre / Troalen, Frédéric / Morice, Philippe / Haie-Meder, Christine / Culine, Stéphane / Lhommé, Catherine. ·Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France. ·Eur J Cancer · Pubmed #20851596.

ABSTRACT: BACKGROUND: Ovarian yolk sac tumour (OYST) is a very rare malignancy arising in young women. Our study aimed to evaluate long-term outcomes and to identify prognostic parameters likely to help make appropriate risk-based decisions about therapy in this disease. METHODS: This retrospective study is based on prospectively recorded OYST cases at the Institut Gustave-Roussy. A univariate analysis using the logrank test evaluated possible associations between survival and patient or disease covariates. The multivariate analysis was performed using the Cox proportional hazard regression method. RESULTS: Between 1976 and 2006, 84 patients were registered. Since 1991, most of the patients have undergone fertility-sparing surgery. With a median follow-up of 71 months, the overall 5-year and event-free survival rates are 84% and 79%, respectively. In the multivariate model only the absence of ascites and a favourable serum AFP decline rate were significantly associated with better overall survival. CONCLUSIONS: Patients with a poor prognosis factor such as an unfavourable serum AFP decline may be considered for aggressive treatment whereas those with good prognostic factors could be given less courses of chemotherapy.

10 Article [Effects of radiotherapy (external and/or internal) and chemotherapy on female fertility]. 2010

Morice, Philippe / Uzan, Catherine / Gouy, Sébastien / Pautier, Patricia / Lhomme, Catherine / Balleyguier, Corinne / Duvillard, Pierre / Haie-Meder, Christine. ·Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France. philippe.morice@igr.fr ·Bull Acad Natl Med · Pubmed #21171243.

ABSTRACT: The impact of chemotherapy on a woman's fertility depends on her age and the types and doses of the drugs used. Alkylating agents have the biggest negative impact on ovarian function. A trial is currently examining the use of a GnRH agonist to protect ovarian function. The impact of external radiation therapy and brachytherapy on the ovaries depends on three factors: the patient's age, the dose delivered to the ovaries, and concurrent use of chemotherapy. Ovarian transposition is a simple surgical procedure that can be used in selected cases to reduce the risk of early menopause. Both external and internal radiation has an impact on the uterus, notably by altering its vascularization and by reducing its growth when treatment is delivered during childhood.

11 Article Fertility preserving management in gynecologic cancer patients: the need for centralization. 2010

Kesic, Vesna / Rodolakis, Alexandros / Denschlag, Dominik / Schneider, Achim / Morice, Philippe / Amant, Frederic / Reed, Nicholas. ·ESGO Task Force for Fertility Preservation in Gynecologic Cancer, Geneva, Switzerland. vek1@open.telekom.rs ·Int J Gynecol Cancer · Pubmed #21119372.

ABSTRACT: Preservation of fertility has became a very important issue in gynecologic oncology. It is a result of both the increasing incidence of gynecologic cancer in young patients and the increasing age at first pregnancy. Today, in a young patient with a gynecologic cancer, preservation of fertility is possible and depends primarily on the extent and type of cancer. The clinical importance of an appropriate management of young patients with gynecologic cancer has lead the ESGO Task Force for Fertility Preservation in Gynecologic Cancer to conduct a survey with the aim of exploring the numbers and eligibility of gynecologic cancer patients for fertility-sparing treatment in selected gynecologic oncology centers across Europe. A questionnaire designed to allow adequate insight into the number of patient eligible for fertility-sparing treatment and the resulting treatment was sent to 20 ESGO-accredited centers. The data were collected retrospectively for the year 2007. The reply was received from 14 gynecologic oncology centers, and those surveys were included for analysis. The small numbers of patients eligible for conservative management (14-15 per year/median number in ESGO-accredited centers) and even the smaller number of those who actually receive fertility-sparing treatment (<10) raise the question of quality of care for these patients. These low numbers support the concept of centralization for fertility-sparing management to improve the quality of patients care. Since carrying out the survey on fertility-sparing management in ESGO-accredited gynecologic oncology centers in Europe, the ESGO Task Force for Fertility Preservation in Gynecologic Cancer has proposed a protocol for referrals to centralized units that have developed specific expertise. Optimal management for young patients with gynecologic cancer should include a clear decision-making process, an adequate counseling about the future oncological and obstetrical risks, the appropriate management, and a careful follow-up within a multidisciplinary setting.

12 Article Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern. 2009

Laurent, I / Uzan, C / Gouy, S / Pautier, P / Duvillard, P / Morice, P. ·Department of Surgery, Institut Gustave-Roussy, Villejuif, France. ·BJOG · Pubmed #19432576.

ABSTRACT: The aim of this study was to assess the outcomes of women treated conservatively for a serous borderline ovarian tumour with stromal microinvasion (SBOT-SMI) but without micropapillary pattern. Ten women treated conservatively for a stage I (n= 8) or stage IIIB (n= 2) tumour were followed up. With a median follow-up duration of 62 months (range 7-117 months), five recurrences developed on the preserved ovary. All lesions were borderline recurrences (with noninvasive peritoneal implants in one). All women are currently disease free. Three women achieved a spontaneous pregnancy and three became pregnant after an in vitro fertilisation procedure. This study suggests that conservative treatment of SBOT-SMI is safe.